-

Nomi Health Announces Advisory Board to Guide Integrated Care Programs, Closing Most Care Gaps for Providers and Plans

Company Introduces Success Care to Tackle Substance Use Disorder Treatment

SALT LAKE CITY--(BUSINESS WIRE)--Nomi Health announced the formation of an advisory board composed of top policy, executive, medical and legal experts to guide and advise on the development of solutions for its customers, including providers, self-funded employers, governments and their partners. Specifically, Nomi’s Integrated Programs give providers and health plans, through a whole-person approach, an end-to-end infrastructure that identifies, closes and monitors gaps in care for populations in need of specific care.

The board brings expertise across multiple healthcare disciplines from epidemiology to behavioral health policy:

● With 25 years of experience in public health, epidemiologist and retired Assistant Surgeon General Dr. Ali Khan has a global reputation for scientific and programmatic excellence in infectious diseases, global health and health security.

● Founder and CEO of The Quell Foundation Kevin Lynch has dedicated more than 20 years of his career to reducing the number of suicides, overdoses and incarcerations of people with mental health illness.

● Founder and CEO of Behavioral Health Tech, the largest community focused on expanding access to mental health and substance use services, Solome Tibebu promotes the advancement of behavioral health access through technology and innovation.

● Managing Partner at Social Innovation Venture Dr. Andrey Ostrovsky, MD is a notable investor, senior operating leader and health policy expert with over a decade of experience applying human-centered design and entrepreneurial principles to make progress addressing health disparities. His expertise includes population health, value-based payment, social determinants of health and quality measurement.

● Partner and Executive Director of Christie 55 Solutions Rich Bagger is a public affairs and policy leader with extensive government, nonprofit and corporate experience providing strategic counsel on business strategies amid complex public policy and regulatory challenges at the state, federal and international levels.

“Taking on healthcare’s biggest challenges is what we do as a company, and we are grateful for the guidance of this board to ensure we’re pushing ourselves and the healthcare category forward in developing meaningful solutions,” said Mark Newman, co-founder and CEO of Nomi Health. “Our Integrated Programs replace fragmented patient engagement and disparate provider networks that create friction and poor performance, and leaves specific populations underserved.”

Nomi Health’s Integrated Programs, including Success Care, a unique substance use disorder (SUD) treatment program, provides end-to-end and streamlined whole-person care to help ensure connected and seamless access to care delivery. Bridging clinical and social care needs, Success Care supports those who are underserved and marginalized, including Medicare and Medicaid beneficiaries and those struggling with SUDs or in the justice system.

“We are putting the advisory board to work immediately in our program focused on serious issues threatening communities nationwide today. Where other solutions don’t go far enough, ours addresses all aspects of the complex care journey and meets people where they are in their care and recovery journey,” said Sara Ratner, president of complex care and government programs at Nomi Health. “Our program removes hurdles in the system that often prevent care and sustained recovery.”

The integrated care model has experienced substantial demand in the market with a 450% year-over-year increase in patient visits. The program also has proven 139% higher engagement in certain Healthcare Effectiveness Data and Information Set (HEDIS) gap measure performance compared to the National Committee for Quality Assurance (NCQA) average.

For more information, visit https://www.nomihealth.com/business/substance-use-disorder-program.

About Nomi Health

Nomi Health powers a new model of healthcare for buyers of care and their partners. The company simplifies the business of healthcare with payment rails and programs built specifically for self-funded employers, governments and their partners, such as TPAs, brokers and consultants.

At Nomi Health, our long-term mission is to rebuild U.S. healthcare to run at half the cost. Nomi delivers actionable analytics, direct access to medical and pharmacy services, and real-time payment rails to transform how providers deliver great healthcare to plans and programs.

Founded in 2019, Nomi Health serves more than 3,200 customers nationwide, impacting 30 million lives and influencing over $150 billion in healthcare spend. Learn more at www.nomihealth.com.

Nomi Health


Release Versions

More News From Nomi Health

CerpassRx Launches AI Engine Powered By Waltz Health to Deliver Real-Time Savings and Spend Management for Specialty Drugs

DALLAS & CHICAGO--(BUSINESS WIRE)--CerpassRx, a leader in pharmacy benefit management (PBM), today announced the launch of the Intelligent Specialty Engine, an AI-enabled platform powered by Waltz Health to manage specialty drug spend. CerpassRx’s innovative approach includes real-time analytics and specialty spend management capabilities that drive significant cost savings, improve transparency and optimize the specialty drug experience for health plan customers and their members – or self-ins...

CareSource and Nomi Health Launch Innovative Partnership to Improve Healthcare Access and Outcomes

DAYTON, Ohio--(BUSINESS WIRE)--CareSource, a non-profit health plan with over 2 million members, has selected Nomi Health to partner with it in launching a new comprehensive effort to help close gaps in healthcare access and outcomes for its Medicaid members across Ohio, Georgia, and Indiana. This collaboration aims to enhance access to essential healthcare services and improve overall health outcomes for people facing barriers to care. "This partnership with Nomi Health represents a significan...

Weight Loss Drugs Weigh Heavy on Employer Health Plans

OREM, Utah--(BUSINESS WIRE)--A meteoric rise in the popularity of glucagon-like peptide-1 (GLP-1) medications such as Ozempic, Wegovy and Mounjaro is creating financial challenges for employer-sponsored health plans. New data from Nomi Health, a company changing healthcare economics, reveals that spending on these diabetes and weight loss drugs went up 253% from 2020 to 2023, surpassing $1 billion last year and making up nearly 10% of total prescription costs for employers. Nomi Health analyzed...
Back to Newsroom